Dexmedetomidine reduces postoperative acute kidney injury risk

Dexmedetomidine significantly decreases postoperative acute kidney injury (AKI) incidence compared to controls (RR 0.60, 95% CI 0.45-0.78), shortening ICU and hospital stay but increasing bradycardia risk. Meta-analysis of 25 trials (n=3,997) demonstrates its efficacy in AKI prevention post-surgery, offering potential benefits in patient outcomes.